Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions - Vultaggio, A.; Petroni, G.; Pratesi, S.; Nencini, F.; Cammelli, D.; Milla, M.; Prignano, F.; Annese, V.; Romagnani, S.; Maggi, E.; Matucci, A. (Clinical and experimental immunology, 2016)
Keywords: Adult; Aged; allergy; Antirheumatic Agents - adverse effects; arthritis; Cell growth; Cytokines; Cytokines - metabolism; Drug Hypersensitivity - blood; Drug Hypersensitivity - immunology; Female; Humans; Immune System Diseases - complications; Immune System Diseases - drug therapy; Immune System Diseases - immunology; Immunoglobulin E - immunology; Immunoglobulins; Infliximab - adverse effects; Infliximab - therapeutic use; Isoantibodies - blood; Isoantibodies - immunology; Lymphocyte Activation - immunology; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Original; T cells; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; allergy; cytokines; arthritis; T cells